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INTRODUCTION
Surgical rescue has become a catch phrase for the Surgeon’s role in management of
variceal bleeding1. This is largely because of the current popularity of pharmacolo-
gic portal pressure reduction and the widespread use of endoscopic sclerotherapy.
These two therapies both reduce the risk of rebleeding from varices by approxima-
tely 50%, but even then 30-40% of patients will rebleed through propranolol and/
or sclerotherapy. Surgical options are reserved for patients who rebleed through
these therapies or alternatively for patients in whom the high rebleeding risk is
unacceptable.
This paper addresses the current role of decompressive shunts and liver trans-
plantation in management of variceal bleeding.
Patient Evaluation
Acute variceal bleeding can usually be stopped by endoscopic sclerotherapy. When
stabilized the patient should be evaluated for the risk of further bleeding and the
underlying cause of the portal hypertension. Emphasis of the latter should be on
the severity of the underlying liver disease. Most deaths in patients with variceal
bleeding are from liver failure.
History, physical examination, and standard laboratory tests of biochemical and
haematologic indices provide the basis of evaluation. Ascites, encephalopathy and
poor nutritional status indicate advanced disease, and when supported by elevated
bilirubin, coagulopathy and hypoalbuminaemia suggest to a surgeon that the
patient is a poor candidate for any operation other than a liver transplant.
Endoscopy, vascular imaging techniques, liver biopsy and quantitative liver func-
tion testing can all be useful in evaluating the patient with more subtle disease, and
in making therapy choices.
Correspondence to: J. Michael Henderson, FRCS, Department of Surgery, Emory University School of
Medicine, Atlanta, Georgia 30322
2728 J. M. HENDERSON
Decompressive Shunts
These fall into three groups: total portal systemic shunts, partial portal decompres-
sion, and selective variceal decompression.
Total shunts are either the classic end-to-side portacaval shunt or a variety of
side-to-side shunts such as portacaval, mesocaval, central splenorenal2. The latter
decompress the hepatic sinusoids in addition to relieving splanchnic hypertension.
All control variceal bleeding, but loss of portal perfusion accelerates liver failure.
Current data suggest that patients with alcoholic cirrhosis tolerate total shunts
better than nonalcoholic paitents3. Continued massive variceal bleeding can be
stopped by a total.shunt: if subsequent transplant is a consideration a mesocaval
shunt is preferred as it does not disturb the liver hilus. A further indication for a
total portal systemic shunt is acute Budd-Chiari Syndrome when a side-to-side
shunt decompresses the obstructed sinusoids and can stop the progression of
hepatocyte necrosis4.
Partial Portal Decompression can be achieved with an 8mm interposition porta-
caval H-graft5. At this diameter of shunt portal pressure is reduced to approxima-
tely 12 mm Hg, which is similar to the level of portal pressure below which no
bleeding occurs in the pharmacologic studies. Portal perfusion is maintained in
82% of patients with this diameter of shunt.
Currently, more data needs to be collected on these shunts, and controlled
studies are required to confirm their haemodynamic efficacy and clinical role.
Selective variceal decompression is most commonly achieved by distal splenore-
nal shunt (DSRS)6. Control of variceal bleeding is as good with selective shunt as a
total shunt, and is achieved in approximately 90% of patients2. The physiologic
goal of maintaining portal perfusion is significantly better achieved in nonalcoholic
(90%) patients than alcoholic (50%) after standard DSRS7. Addition of splenopan-
creatic disconnection, taking the entire splenic vein out of the pancreas, improves
maintenance of portal flow in alcoholics to 84% Survival parallels these portal
perfusion differences, being significantly better for non-alcoholics compared to
alcoholics after standard DSRS9’1, and being improved in alcoholic patients by
splenopancreatic disconnection (Figure 1.)
Prospective randomized clinical trials comparing DSRS to a variety of total
shunts in predominantly (83%) alcoholic patients shows similar control of bleeding,
operative mortality and longterm survival2’3’11.
Sclerotherapy Versus Shunt
Five prospective randomized trials have compared endoscopic sclerotherapy to
shunt surgery12-6. The common finding to these studies was improved control of
variceal bleeding with shunt surgery. The data on survival is less clear.
The first study
2 compared sclerotherapy to emergency portacaval shunt in
patients with alcoholic cirrhosis and acute variceal bleeding. Both early and late
control of bleeding was better in the shunt group. Survival was not significantly
different between groups, but a feature of this study was the role of surgical rescue
of patients with persistent or late rebleeding from varices.
The other four studies compared sclerotherapy to distal splenorenal shunt. The
consistent feature was significantly better bleeding control in the DSRS group.
Three studies
14-16 showed no significant difference in survival in the two groups,SHUNT AND TRANSPLANT IN VARICEAL BLEEDING 29
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Figure Alcoholic versus nonalcoholic cirrhosis survival patterns after distal splenorenal shunt. On the
right, alcoholic cirrhotic patients have significantly poorer survival than nonalcoholic patients after
standard DSRS, while on the left this difference is not seen after DSRS with splenopancreatic
disconnection. (Reproduced with permission from Annals of Surgery, 1989; 210:332-341.
while one showed improved survival in the group randomized to sclerotherapy13.
This latter study13, from our group, again emphasizes the importance of appropri-
ate surgical rescue therapy in patients who fail sclerotherapy. Thirty five percent of
patients failed sclerotherapy, and it was the successful surgical salvage of these
patients who made the difference in survival between these groups. Further, this
survival advantage was seen only in patients with alcoholic cirrhosis (Figure 2)
supporting a treatment strategy of initial sclerotherapy with decompressive shunt
reserved for those with rebleeding. In the nonalcoholic patients, the similar survival
in the two groups combined with the significantly better bleeding control with
DSRS, favors shunt as primary therapy.
Liver Transplantation
The evolution of liver transplantation to a viable clinical therapy
17 in the past
decade means that it must always be considered in management decisions. The
indication for this therapy is end-stage liver disease. Variceal bleeding is certainly
one of the more lethal complications of cirrhosis and portal hypertension, but not
all patients with variceal bleeding have end-stage disease. Several papers or reviews
have addressed the role of liver transplant in management of variceal bleeding18-2.
Clearly, not all pateints with variceal bleeding can or should be managed by liver
transplantation. While the concept of a curative rather than a palliative procedure
for such patients is attractive, the risk: benefit ratio must be weighed for each
patient. The decision to transplant a patient with variceal bleeding is easy if they
are Child’s Class C and otherwise fulfill transplant criteria. Equally, the decision to
not transplant should be easy for good risk Child’s A patients in whom lesser
therapies effective in control of variceal bleeding can be offered, with a relatively
low risk of rapid progression to liver failure. More problematic are the middle risk30 J.M. HENDERSON
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Figure 2 The different survival pattern of alcoholic and nonalcoholic patients in the Emory prospective
randomized trial
13 comparing DSRS and sclerotherapy. The group with significant survival advantage
are the alcoholic cirrhosis patients who receive initial sclerotherapy with surgical rescue of the 35% who
ultimately fail sclerosis.
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Figure 3 Algorithm of management for prevention of recurrent variceal bleeding.SHUNT AND TRANSPLANT IN VARICEAL BLEEDING 31
patients in whom the course of their liver disease may be less predictable: these
patients should perhaps be the target or more objective hepatic function studies to
facilitate making this decision.
What treatment should be used in patients in whom transplant is a likely ultimate
step? Opinions vary. A lesser (and nonoperative) therapy will make subsequent
transplant technically easier, but should a patient be offered transplant early
because of variceal bleeding if their own liver is adequate when their bleeding has
been controlled? If surgery is required urgently as a life saving measure, or
indicated in an elective (and at this time, good risk) patient the two preferred
choices are mesocaval shunt or DSRS.
Summary
Based on our current management of many patients with variceal bleeding and the
availability of all treatment options at our institution, the algorithm of management
given in Figure 3 has evolved.
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